Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 64, Issue 1, 2004, Pages 33-40

  Kølendorf, Klaus ^a   Eriksson, Johan ^b   Birkeland, Kåre I ^c   Kjellström, Thomas ^d   Hreidarsson, Astradur B ^e  

^a KØGE HOSPITAL   (Denmark)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d Landspitali University Hospital ^*

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Dose titration; Repaglinide; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; REPAGLINIDE;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DRUG EFFECT; DRUG TARGETING; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TITRIMETRY; TREATMENT OUTCOME;

EID: 1342302821     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.10.006     Document Type: Article

References (18)

1. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diab. Care 23 (2001) S4-S19.
2. Polonsky K.S., Given B.D., Hirsch L.J.et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 318:1988;1231-1239.
3. Owens D.R., Luzio S.D., Coates P.A. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diab. Med. 13:1996;S159-S165.
4. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837-853.
5. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet. 41:2002;471-483.
6. Owens D.R., Luzio S.D., Ismail I., Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with Type 2 diabetes. Diab. Care. 23:2000;518-523.
7. Fuhlendorff J., Rorsman P., Kofod H.et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 47:1998;345-351.
8. Goldberg R.B., Einhorn D., Luca C.P., Rendell M.S., Damsbo P., Huang W.-C., Strange P., Brodows R.G. A randomized placebo-controlled trial of repaglinide in the treatment of Type 2 diabetes. Diab. Care. 21:1998;1897-1903.
9. Jovanovic L., Dailey G., Huang W.-C., Strange P., Goldstein B.J. Repaglinide in Type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J. Clin. Pharmacol. 40:2000;49-57.
10. Van Gaal L.F., Van Acker K.L., de Leeuw I.H. Repaglinide improves blood glucose control in sulphonylurea-naïve Type 2 diabetes. Diab. Res. Clin. Pract. 53:2001;141-148.
11. Landgraf R., Frank M., Bauer C., Dieken M.L. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int. J. Obes. 24:2000;S38-S44.
12. Moses R.G., Gomis R., Frandsen K.B., Schlienger J.-L., Dedov I. Flexible meal-related dosing with repaglinide facilitates glycaemic control in therapy-naïve Type 2 diabetes. Diab. Care. 24:2001;11-15.
13. Kristensen J.S., Frandsen K.B., Bayen T., Miller P.G. Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylureas. Diabetologia. 42:1999;A4.
14. Madsbad S., Kilhovd B., Lager I., Mustajoki P., Dejgaard A. For the Scandinavian Repaglinide Group: comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabetes Med. 18:2001;395-401.
15. Schmitz O., Lund S., Andersen P.H.et al. Optimizing insulin secretagogue therapy in patients with type 2 diabetes. Diab. Care. 25:2002;342-346.
16. Goldstein D.E., Little R.R., Wiedmeyer H.M., England J.D., McKenzie E.M. Glycated haemoglobin: methodologies and clinical applications. Clin. Chem. 32:1986;B64-B70.
17. Marbury T., Huang W.-C., Strange P., Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diab. Res. Clin. Pract. 43:1999;155-166.
18. American Diabetes Association Consensus Statement, Post-prandial blood glucose, Diab. Care 24 (2001) 775-778.